Hepatocellular carcinoma – Life with Disease

Go back

Hepatocellular carcinoma is the most common form of liver cancer, a serious disease that often develops silently in people with chronic liver conditions. Understanding what lies ahead can help patients and families prepare and make informed decisions about care.

What to Expect: Prognosis and Survival Outlook

Hepatocellular carcinoma is one of the most serious cancers, and it’s important to approach this topic with honesty and compassion. The overall five-year survival rate for people diagnosed with this disease is around 18 to 20 percent, making it one of the cancers with the lowest survival rates, second only to pancreatic cancer in severity.[1][2][3] This number reflects the reality that many people are diagnosed when the disease is already advanced.

However, these statistics don’t tell the whole story. The stage at which hepatocellular carcinoma is discovered makes an enormous difference in what patients can expect. When caught in its very early or early stages, the outlook can be dramatically better. People who are able to have surgery to remove the tumor or receive a liver transplant may have a five-year survival rate greater than 75 percent, with tumor recurrence rates as low as 15 percent at five years.[12] Early-stage patients who receive treatment can sometimes expect to live for ten years or more.[14]

Unfortunately, more than half of all people with hepatocellular carcinoma are diagnosed in an advanced stage.[4] At this point, the disease has typically grown larger, may have spread to nearby blood vessels, or moved to other parts of the body. The median survival for people with late-stage disease is typically between one and three years.[14] The incidence-to-mortality ratio—which measures how many people die compared to how many are diagnosed—is nearly one for hepatocellular carcinoma, meaning almost as many people die from it as are diagnosed with it.[2]

Several factors influence individual prognosis. These include the size and number of tumors, whether the cancer has spread, how well the liver is still functioning, and the person’s overall health and performance status. Most people diagnosed with hepatocellular carcinoma also have underlying cirrhosis, which is severe scarring of the liver. Approximately 80 to 90 percent of hepatocellular carcinoma cases occur in people who already have cirrhosis.[2][3] This combination of cancer and liver disease creates a challenging situation that affects both treatment options and outcomes.

⚠️ Important
Statistics about survival are based on large groups of people and cannot predict what will happen to any individual person. Every person’s situation is unique, and many factors influence outcomes. New treatments are being developed, and some people respond better to treatment than others. It’s important to discuss your personal situation with your healthcare team.

How the Disease Progresses Without Treatment

Understanding the natural progression of hepatocellular carcinoma helps explain why early detection is so critical. In the beginning stages, this cancer grows relatively slowly. However, it is described as an aggressive or fast-growing cancer once it advances beyond the early stages.[2] The disease typically develops in a liver that is already damaged by chronic inflammation from conditions like hepatitis B, hepatitis C, heavy alcohol use, or fatty liver disease.

As the cancer develops, changes occur in the liver cells called hepatocytes. These changes cause the cells to multiply uncontrollably, forming a growth called a tumor. Initially, the tumor may be small and confined to one area of the liver. During this period, many people experience no symptoms at all, which is why the disease often goes undetected.[1][2]

As time passes without treatment, the tumor grows larger and may multiply, forming additional tumors throughout the liver. The cancer can invade and damage healthy liver tissue, reducing the liver’s ability to perform its essential functions. The liver is responsible for breaking down nutrients, filtering toxins from the blood, and supporting healthy blood flow. When cancer interferes with these functions, serious complications develop.[4]

The tumor can also grow into nearby blood vessels, particularly the hepatic artery and portal vein, which supply blood to the liver. When blood vessels are involved, cancer cells can break away and travel through the bloodstream to other parts of the body. This process, called metastasis, most commonly affects the lungs, bones, and other organs.[1]

Eventually, without treatment, hepatocellular carcinoma can lead to liver failure. At this stage, the liver can no longer perform its vital functions, and the body’s systems begin to break down. This is a life-threatening condition that requires intensive medical care. The combination of cancer progression and underlying liver disease makes advanced hepatocellular carcinoma extremely challenging to manage.[2]

Possible Complications

Hepatocellular carcinoma can cause a range of complications, some related to the cancer itself and others to the damaged liver that often accompanies this disease. These complications can significantly affect quality of life and require careful medical management.

One of the most serious complications is portal vein thrombosis, which occurs when a blood clot forms in the main vein that carries blood to the liver, or when the tumor grows directly into this vein. This can worsen liver function and complicate treatment options.[14] When the portal vein is blocked, pressure builds up in the veins that drain into it, leading to further complications throughout the digestive system.

As the liver becomes more damaged, fluid can accumulate in the abdomen, a condition called ascites. People with ascites often notice their stomach becoming swollen and distended, and they may feel uncomfortable or have difficulty breathing when fluid builds up significantly.[2] This fluid accumulation is a sign of advanced liver disease and requires treatment with medication or procedures to remove the fluid.

Another complication is hepatic encephalopathy, a condition where toxins that the damaged liver can no longer filter properly build up in the bloodstream and affect brain function. This can cause confusion, changes in personality, difficulty concentrating, or in severe cases, loss of consciousness. It’s a frightening complication for both patients and families to witness.

Jaundice, where the skin and whites of the eyes turn yellow, occurs when the liver cannot process a substance called bilirubin. This often accompanies other symptoms like dark urine and pale stools.[2] Jaundice is usually a sign of significant liver dysfunction.

People with hepatocellular carcinoma may also develop enlarged veins in the esophagus or stomach, called varices. These can rupture and bleed, causing vomiting of blood or black, tarry stools. This is a medical emergency that requires immediate attention. The bleeding occurs because increased pressure in the portal vein system forces blood to find alternative routes.

Weight loss and severe fatigue are common complications as the disease progresses. The cancer can cause loss of appetite, and people may feel full after eating only small amounts. The body’s metabolism changes, and maintaining adequate nutrition becomes increasingly difficult.[2] Some people also experience persistent nausea, vomiting, and unexplained itching all over their body.

Pain in the upper right side of the abdomen or the right shoulder can develop as the tumor grows and stretches the liver capsule. This pain may be constant or come and goes, and it can significantly impact daily activities and sleep.[7]

Impact on Daily Life

Living with hepatocellular carcinoma affects nearly every aspect of a person’s daily routine, from physical capabilities to emotional well-being and social relationships. The disease and its treatments can create challenges that require significant adjustments and ongoing support.

Physically, many people experience profound fatigue that goes beyond normal tiredness. This isn’t the kind of fatigue that improves with rest. It can make simple activities like getting dressed, preparing meals, or walking short distances feel exhausting. The fatigue often stems from the liver’s reduced ability to produce energy, anemia from the disease, or the effects of treatment.[2]

Changes in appetite and weight loss can be particularly distressing. Many people find that food no longer tastes appealing, or they feel full after eating very little. This can lead to nutritional deficiencies and muscle loss, creating a cycle where weakness increases and recovery becomes harder. Family meal times, once a source of connection, may become stressful as loved ones worry about the person eating enough.

Pain management becomes a daily concern for many patients. Discomfort in the abdomen or shoulder may require medications that themselves can cause side effects like drowsiness or constipation. Finding the right balance between pain relief and maintaining alertness and quality of life requires ongoing communication with healthcare providers.

Work and professional life often need adjustment. Some people can continue working, especially in the early stages or if they respond well to treatment. Others may need to reduce their hours, take medical leave, or stop working entirely. This can create financial stress on top of medical concerns, and many people struggle with the loss of identity and purpose that comes with leaving a career they valued.

Social relationships may change as well. Some people find that friends and acquaintances don’t know what to say or gradually drift away. The unpredictability of symptoms can make it difficult to commit to social plans. On the other hand, many people find that their closest relationships deepen, and they discover new sources of support in unexpected places.

Emotional challenges are significant and deserve recognition. Anxiety about the future, fear of pain, worry about loved ones, and grief for losses already experienced are all common. Depression can develop, especially when symptoms are severe or treatment side effects are difficult to manage. Seeking support from counselors, support groups, or mental health professionals who specialize in cancer care can be extremely helpful.

Treatment schedules can dominate daily life. Regular appointments for blood tests, imaging scans, infusions, or other procedures require time, energy, and often significant travel. The logistics of coordinating care, managing medications, and keeping track of appointments can feel like a full-time job.

Hobbies and activities that once brought joy may need to be adapted. Someone who loved gardening might need to work in shorter sessions with frequent breaks. An avid reader might struggle with concentration due to medication side effects. Finding ways to maintain connections to meaningful activities, even in modified forms, can provide important moments of normalcy and pleasure.

Practical considerations also arise. People may need help with household tasks like cleaning, laundry, or grocery shopping. They may need assistance getting to appointments or managing medications. Accepting help can be difficult for those who valued their independence, and learning to ask for and receive support is itself an adjustment.

⚠️ Important
The impact of hepatocellular carcinoma varies greatly from person to person. Some people maintain relatively good function for extended periods, while others experience rapid changes. Open communication with your healthcare team about how symptoms affect your daily life is essential. They can offer supportive care measures like pain management, nutrition counseling, or referrals to specialists who can help with specific challenges.

Support for Families: Understanding Clinical Trials

For families supporting someone with hepatocellular carcinoma, understanding clinical trials can open doors to additional treatment options and give hope during a difficult time. Clinical trials are research studies that test new approaches to preventing, detecting, or treating diseases. They are carefully designed and monitored to ensure patient safety while advancing medical knowledge.

Currently, hundreds of clinical trials are being conducted for hepatocellular carcinoma worldwide. These trials test new medications, combinations of existing treatments, innovative surgical techniques, and novel approaches to care. Some trials focus on early-stage disease, while others explore options for people with advanced cancer who have exhausted standard treatment options.[6]

Families should know that participating in a clinical trial is always voluntary. The decision to join a trial should be made after careful discussion with the healthcare team, who can explain the potential benefits and risks. Not everyone is eligible for every trial; researchers establish specific criteria based on the stage of disease, previous treatments received, overall health status, and other factors.

One important aspect of clinical trials is that they offer access to cutting-edge treatments before these become widely available. For hepatocellular carcinoma, recent trials have explored combinations of immunotherapy drugs, which help the body’s immune system fight cancer, paired with medications that target blood vessel growth in tumors. Some of these combinations have shown promising results and have subsequently been approved for standard use.[6]

Families can help their loved one explore clinical trial options in several practical ways. First, they can research available trials through websites like ClinicalTrials.gov, where studies are listed with detailed information about eligibility criteria and locations. They can also ask the patient’s oncologist or hepatologist about trials available at their treatment center or nearby institutions.

Understanding the trial’s design is important. Some trials compare a new treatment to the current standard treatment, meaning participants might receive either the new approach or existing therapy. Others test the new treatment in everyone enrolled. The informed consent process, where researchers explain all aspects of the study, is designed to ensure patients and families understand exactly what participation involves.

Practical support matters enormously. Clinical trials often require additional appointments beyond standard care for monitoring, blood tests, or imaging scans. Families can help by providing transportation, attending appointments to help remember information discussed, keeping organized records of medications and side effects, and serving as advocates if concerns arise.

It’s also worth knowing that participation in a clinical trial can be stopped at any time if the patient chooses. People are not locked into continuing if they experience intolerable side effects or simply decide it’s not right for them. The decision to participate or withdraw is always the patient’s to make.

For families considering clinical trials, questions to ask the research team include: What is the purpose of this trial? What treatments will my loved one receive? What are the possible side effects? How often will they need to come for appointments? What happens if the treatment doesn’t work? Will there be additional costs? These conversations help families make informed decisions.

Beyond the potential medical benefits, some patients and families find meaning in contributing to research that may help others in the future. Even if the treatment doesn’t ultimately help the individual participant, the knowledge gained can advance understanding and improve care for future patients.

Support groups and patient advocacy organizations focused on liver cancer can also provide valuable information about clinical trials and connect families with others who have gone through similar experiences. Many of these organizations maintain lists of available trials and can help families navigate the process of finding appropriate studies.

💊 Registered drugs used for this disease

List of officially registered medicines that are used in the treatment of this condition, based only on the provided sources:

  • Sorafenib – A tyrosine kinase inhibitor approved for systemic treatment of advanced hepatocellular carcinoma
  • Lenvatinib – A tyrosine kinase inhibitor approved as first-line systemic therapy for advanced hepatocellular carcinoma
  • Regorafenib – A tyrosine kinase inhibitor approved for second-line treatment after sorafenib in advanced hepatocellular carcinoma
  • Cabozantinib – A tyrosine kinase inhibitor approved for patients who have been previously treated with sorafenib
  • Ramucirumab – A VEGF inhibitor approved for patients with elevated alpha-fetoprotein who have been previously treated with sorafenib
  • Atezolizumab plus Bevacizumab – A combination of a PD-L1 checkpoint inhibitor and a VEGF inhibitor approved for first-line treatment of advanced hepatocellular carcinoma
  • Durvalumab (IMFINZI) plus Tremelimumab (IMJUDO) – A combination of checkpoint inhibitors approved for treatment of unresectable hepatocellular carcinoma
  • Nivolumab – A checkpoint inhibitor that has received accelerated FDA approval for previously treated hepatocellular carcinoma
  • Pembrolizumab – A checkpoint inhibitor that has received accelerated FDA approval for previously treated hepatocellular carcinoma

Ongoing Clinical Trials on Hepatocellular carcinoma

  • Long-term Safety Study of Vusolimogene Oderparepvec, RP2, and RP3 in Patients with Melanoma, Liver Cancer, or Advanced Solid Tumors

    Recruiting

    1 1 1
    Investigated diseases:
    France Germany Greece Poland Spain
  • A study to investigate the safety and effects of ceralasertib, tremelimumab, and durvalumab in adults with various solid tumors

    Recruiting

    1 1 1
    Poland
  • Study of durvalumab and tremelimumab with or without hepatic arterial infusion of gemcitabine and oxaliplatin in patients with high tumor burden hepatocellular carcinoma

    Recruiting

    1 1 1 1
    Investigated diseases:
    France
  • Study of Gallium (68Ga) edotreotide, Fluorocholine (18F) and Fludeoxyglucose (18F) PET imaging for detection and staging of liver cancer and gastro-entero-pancreatic tumors

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France
  • Study of Rilvegostomig with Bevacizumab and Tremelimumab as First-line Treatment for Patients with Advanced Liver Cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    France Germany Italy The Netherlands Poland Spain
  • Study on Early Detection of Liver Cancer Using Hyperpolarized Pyruvate MRI for Patients with Primary Liver Cancer

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Denmark
  • Study of drug combinations including cisplatin, carboplatin, doxorubicin, fluorouracil, vincristine, etoposide, irinotecan, gemcitabine, oxaliplatin and sorafenib for children with hepatoblastoma or hepatocellular carcinoma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Austria Belgium Czechia France Germany Ireland +4
  • Study on the Safety of Atezolizumab and Bevacizumab for Liver Transplant Patients with Advanced Liver Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    France
  • Study on Liver Cancer in Cirrhosis Patients Using Idarubicin and Lipiodol Injection

    Recruiting

    1 1 1
    Investigated diseases:
    France
  • Study of Fecal Microbiota Transplantation combined with atezolizumab and bevacizumab in patients with unresectable liver cancer who progressed after initial treatment

    Recruiting

    1 1 1
    Investigated diseases:
    Italy

References

https://www.mayoclinic.org/diseases-conditions/hepatocellular-carcinoma/symptoms-causes/syc-20589101

https://my.clevelandclinic.org/health/diseases/21709-hepatocellular-carcinoma-hcc

https://www.ncbi.nlm.nih.gov/books/NBK559177/

https://www.imfinzi.com/hepatocellular-carcinoma/what-is-hcc.html

https://liverfoundation.org/liver-diseases/cancer/hepatocellular-carcinoma/

https://www.nature.com/articles/s41572-020-00240-3

https://liver.org.au/your-liver/liver-cancer/hcc/

https://umiamihealth.org/en/sylvester-comprehensive-cancer-center/treatments-and-services/liver-and-bile-duct-cancer/hepatocellular-cancer-hcc

https://my.clevelandclinic.org/health/diseases/21709-hepatocellular-carcinoma-hcc

https://pmc.ncbi.nlm.nih.gov/articles/PMC4381163/

https://www.mayoclinic.org/diseases-conditions/hepatocellular-carcinoma/symptoms-causes/syc-20589101

https://emedicine.medscape.com/article/197319-treatment

https://www.mdanderson.org/cancerwise/what-is-new-in-treating-hepatocellular-carcinoma–the-most-common-liver-cancer.h00-159617856.html

https://www.aasld.org/liver-fellow-network/core-series/why-series/why-does-treatment-hepatocellular-carcinoma-require

https://www.cancer.gov/types/liver/what-is-liver-cancer/treatment

https://my.clevelandclinic.org/health/diseases/21709-hepatocellular-carcinoma-hcc

https://www.cancercare.org/publications/238-coping_with_liver_cancer

https://liverfoundation.org/liver-diseases/cancer/hepatocellular-carcinoma/

https://www.cancer.org/cancer/types/liver-cancer/after-treatment/follow-up.html

https://pmc.ncbi.nlm.nih.gov/articles/PMC8750465/

https://www.mayoclinic.org/diseases-conditions/liver-cancer/diagnosis-treatment/drc-20353664

https://medlineplus.gov/diagnostictests.html

https://www.questdiagnostics.com/

https://www.healthdirect.gov.au/diagnostic-tests

https://www.who.int/health-topics/diagnostics

https://www.yalemedicine.org/clinical-keywords/diagnostic-testsprocedures

https://www.nibib.nih.gov/science-education/science-topics/rapid-diagnostics

https://www.health.harvard.edu/diagnostic-tests-and-medical-procedures

https://www.roche.com/stories/terminology-in-diagnostics

FAQ

Can hepatocellular carcinoma be cured?

Yes, hepatocellular carcinoma can potentially be cured if caught at a very early stage. Surgery to remove the tumor or a liver transplant can be curative treatments for early-stage disease. People who receive these treatments may have five-year survival rates greater than 75 percent. However, most people are diagnosed at later stages when cure becomes much more difficult.

Why don’t symptoms appear until hepatocellular carcinoma is advanced?

In its early stages, hepatocellular carcinoma grows slowly and may not interfere enough with liver function to cause noticeable symptoms. The liver is also a resilient organ that can continue functioning even when partially damaged. By the time symptoms like pain, weight loss, or jaundice appear, the cancer has typically grown larger or spread. This is why regular screening is so important for people at high risk.

Who should be screened for hepatocellular carcinoma?

Regular screening is recommended for people with cirrhosis from any cause, people with chronic hepatitis B infection (particularly those of Asian or African heritage, or with a family history of liver cancer), and increasingly, people with metabolic dysfunction-associated steatotic liver disease (MASLD). Screening typically involves an ultrasound and sometimes a blood test for alpha-fetoprotein every six months.

What is the connection between hepatocellular carcinoma and cirrhosis?

Approximately 80 to 90 percent of people diagnosed with hepatocellular carcinoma have underlying cirrhosis, which is severe scarring of the liver. Cirrhosis develops from chronic liver inflammation caused by conditions like hepatitis B, hepatitis C, heavy alcohol use, or fatty liver disease. The long-term inflammation and scarring create an environment where liver cells are more likely to undergo cancerous changes.

Are there lifestyle changes that can reduce the risk of hepatocellular carcinoma?

Yes, several lifestyle measures can reduce risk. These include maintaining a healthy weight, avoiding excessive alcohol consumption, not smoking, getting vaccinated against hepatitis B, eating a diet rich in vegetables and fiber while limiting red meat and sugar, and staying physically active. For people already diagnosed with liver disease, these measures can help slow disease progression and potentially reduce cancer risk.

🎯 Key takeaways

  • Hepatocellular carcinoma accounts for 85-90% of primary liver cancers and is the third leading cause of cancer-related deaths worldwide.
  • Early detection dramatically improves survival—five-year survival can exceed 75% for early-stage disease versus 1-3 years median survival for advanced stages.
  • Most people have no symptoms in early stages, which is why regular screening is critical for those with cirrhosis or chronic liver conditions.
  • About 80-90% of hepatocellular carcinoma cases occur in people who already have cirrhosis from hepatitis, alcohol, or fatty liver disease.
  • Multiple new treatment options have been approved in recent years, including combinations of immunotherapy and targeted drugs.
  • The disease affects not just physical health but emotional well-being, work life, relationships, and daily activities in profound ways.
  • Clinical trials offer access to cutting-edge treatments and contribute to advancing knowledge that helps future patients.
  • Family support is invaluable—from helping with appointments and practical tasks to researching clinical trial options and providing emotional care.

Connected medications: